Following Glaukos’ acquisition of Avedro in 2019, the company is poised to introduce a range of new corneal health products into the Australian and New Zealand markets to complement its innovative micro-invasive glaucoma surgery (MIGS) iStent technologies.
“In November 2019 Glaukos’ acquisition of Avedro combined two complementary, hybrid pharmaceutical and device ophthalmic organisations, establishing the cornerstone for Glaukos’ new corneal health franchise,” said Glenn Fawcett, Glaukos’ Australia-based general manager. “Over the past 12 months we have been preparing to deliver this business directly in Australia and through our distribution partners, Toomac, in New Zealand. Glaukos plans to leverage our proven market-building expertise to help expand this market and prepare for more innovative product and treatment launches in the years to come.”
Glaukos is now combining its MIGS product pipeline with Avedro’s cross-linking drug formulations, designed to strengthen corneal tissue to prevent the progression of keratoconus. “Avedro is an ideal fit for Glaukos’ core strengths in creating and disrupting ophthalmic markets with novel therapies that address important unmet clinical needs of practitioners and patients,” said Thomas Burns, Glaukos president and chief executive officer, when announcing the acquisition.
Glaukos has also appointed Neville White to support the rollout of its corneal health business in Australasia.